Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Functional Diarrhea Clear all
Completed Not applicable Interventional

GI Alpha-Gal Study

NCT06268717
View directory record Official record
Conditions
Alpha-Gal Syndrome, Irritable Bowel Syndrome, Diarrhea, Abdominal Pain, Vomiting
Interventions
Ground pork containing alpha-gal, Pork meat not containing alpha-gal
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

NCT03721107
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Blautix, Placebo
Biological · Other
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years to 70 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 8, 2026, 8:38 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

NCT01268618
View directory record Official record
Conditions
IBS-D and Functional Dyspepsia
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Duluth, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 4 Interventional

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

NCT03729271
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, Glucose and lactulose hydrogen breath testing
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Change in Permeability of the Small Intestine After Treatment With Gluten

NCT02098057
View directory record Official record
Conditions
Gastrointestinal Disorders
Interventions
Gluten Healthy, Placebo
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Not listed No phase listed Observational

Microbial and Human Determinants of the Onset of IBD Flares

NCT05463900
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated, Crohn Disease in Remission
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

Diarrhea Predominant Irritable Bowel Syndrome in Females

NCT00461526
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
43
States / cities
Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 8, 2026, 8:38 AM EDT
Withdrawn Phase 3 Interventional

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT04612803
View directory record Official record
Conditions
Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea
Interventions
Antihistamine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

NCT02328547
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Fecal microbiota transplantation capsules, Placebo capsules
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Hamden, Connecticut • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553591
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
257
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT04129619
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
ORP-101, Placebo
Drug
Lead sponsor
OrphoMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 8, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional Results available

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02120027
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
73
States / cities
Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 8, 2026, 8:38 AM EDT
Terminated Not applicable Interventional

Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

NCT00179582
View directory record Official record
Conditions
IBS
Interventions
VSL#3
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 8, 2026, 8:38 AM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Not applicable Interventional

Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome

NCT01624610
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dietary intervention
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial

NCT00779493
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
curcumin, placebo
Dietary Supplement
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
Interventions
Aldafermin, Placebo
Drug
Lead sponsor
Michael Camilleri, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 8, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01844180
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 8, 2026, 8:38 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

NCT04214470
View directory record Official record
Conditions
Irritable Bowel, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Without Diarrhea, Irritable Bowel Syndrome Aggravated, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome Characterised by Alternating Bowel Habit
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 8, 2026, 8:38 AM EDT